StockData
Allarity Therapeutics, Inc. logo

Allarity Therapeutics, Inc. (ALLR) stock

ALLRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.87+0.03 (+3.69%)

Close on Nov 18, 2026Market cap $13.87MP/E –Yield –

Allarity Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Allarity Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$10.80M. For fiscal 2025 it was -$12.61M. The highest annual figure on record is -$8.32M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.61M–
FY2024Dec 31, 2024-$27.24M–
FY2023Dec 31, 2023-$17.13M–
FY2022Dec 31, 2022-$34.46M–
FY2021Dec 31, 2021-$26.56M–
FY2020Dec 31, 2020-$8.32M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.67M–
Q1 FY2026Mar 31, 2026-$2.69M–
Q4 FY2025Dec 31, 2025-$2.92M–
Q3 FY2025Sep 30, 2025-$2.52M–
Q2 FY2025Jun 30, 2025-$4.13M–
Q1 FY2025Mar 31, 2025-$3.04M–
Q4 FY2024Dec 31, 2024-$7.32M–
Q3 FY2024Sep 30, 2024-$12.31M–
Q2 FY2024Jun 30, 2024-$3.37M–
Q1 FY2024Mar 31, 2024-$4.24M–
Q4 FY2023Dec 31, 2023-$4.88M–
Q3 FY2023Sep 30, 2023-$4.43M–
Q4 FY2022Dec 31, 2022-$6.75M–
Q3 FY2022Sep 30, 2022-$4.56M–
Q2 FY2022Jun 30, 2022-$4.84M–
Q1 FY2022Mar 31, 2022-$18.31M–
Q4 FY2021Dec 31, 2021-$15.74M–
Q3 FY2021Sep 30, 2021-$3.97M–
Q2 FY2021Jun 30, 2021-$4.38M–
Q1 FY2021Mar 31, 2021-$2.46M–
Q4 FY2020Dec 31, 2020-$2.52M–
Q3 FY2020Sep 30, 2020-$1.74M–

More Allarity Therapeutics figures

See a number that looks wrong?